Halozyme Therapeutics, Inc., a biopharmaceutical company, advances disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
As the innovator of ENHANZE drug delivery technology (‘ENHANZE’) with the com…
Analysis
Quality compounder
Halozyme Therapeutics, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is fair. The owner-earnings multiple stands at 19.3×; owner earnings: the cash an owner could take out each year.
Growth is moderate; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202676
76
2026
All-time high
76
Jun 2026
All-time low
76
Jun 2026
Average rank
76
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
53
—
—
—
Price/Earnings
27
—
—
—
Price/Book
29
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
13
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.